172 related articles for article (PubMed ID: 36999934)
1. A nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease.
Xiu W; Zheng J; Zhou Y; Du H; Li J; Li W; Zhou F; Zhou C; Wu F
Cancer Med; 2023 May; 12(10):11375-11384. PubMed ID: 36999934
[TBL] [Abstract][Full Text] [Related]
2. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease.
Choi MK; Hong JY; Chang W; Kim M; Kim S; Jung HA; Lee SJ; Park S; Chung MP; Sun JM; Park K; Ahn MJ; Ahn JS
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1217-25. PubMed ID: 24696125
[TBL] [Abstract][Full Text] [Related]
5. Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study.
Araya T; Kita T; Ueda T; Terada N; Sakai T; Yamamura K; Kurokawa K; Uchida Y; Sone T; Kimura H; Kasahara K
Can Respir J; 2019; 2019():5315903. PubMed ID: 31015884
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
Kenmotsu H; Yoh K; Mori K; Ono A; Baba T; Fujiwara Y; Yamaguchi O; Ko R; Okamoto H; Yamamoto N; Ninomiya T; Ogura T; Kato T
Cancer Sci; 2019 Dec; 110(12):3738-3745. PubMed ID: 31608537
[TBL] [Abstract][Full Text] [Related]
7. A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114).
Sakashita H; Uchibori K; Jin Y; Tsutsui T; Honda T; Sakakibara R; Mitsumura T; Nukui Y; Shirai T; Masuo M; Suhara K; Furusawa H; Yamashita T; Ohba T; Saito K; Takagiwa J; Miyashita Y; Inase N; Miyazaki Y
Thorac Cancer; 2022 May; 13(9):1267-1275. PubMed ID: 35322551
[TBL] [Abstract][Full Text] [Related]
8. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.
Kenmotsu H; Naito T; Mori K; Ko R; Ono A; Wakuda K; Imai H; Taira T; Murakami H; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2015 Mar; 75(3):521-6. PubMed ID: 25563718
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
Hanibuchi M; Kakiuchi S; Atagi S; Ogushi F; Shimizu E; Haku T; Toyoda Y; Azuma M; Kondo M; Kawano H; Otsuka K; Sakaguchi S; Nokihara H; Goto H; Nishioka Y
Lung Cancer; 2018 Nov; 125():93-99. PubMed ID: 30429044
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease.
Yasuda Y; Hattori Y; Tohnai R; Ito S; Kawa Y; Kono Y; Urata Y; Nogami M; Takenaka D; Negoro S; Satouchi M
Jpn J Clin Oncol; 2018 Jan; 48(1):89-93. PubMed ID: 29036303
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
[TBL] [Abstract][Full Text] [Related]
14. Prognostic nomogram based on pre-treatment HALP score for patients with advanced non-small cell lung cancer.
Gao S; Huang Q; Wei S; Lv Y; Xie Y; Hao Y
Clinics (Sao Paulo); 2024; 79():100371. PubMed ID: 38735175
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
Shimizu R; Fujimoto D; Kato R; Otoshi T; Kawamura T; Tamai K; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1159-66. PubMed ID: 25245821
[TBL] [Abstract][Full Text] [Related]
16. Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
Otsubo K; Okamoto I; Hamada N; Nakanishi Y
Respir Investig; 2018 Jul; 56(4):307-311. PubMed ID: 29764748
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.
Okuda K; Hirose T; Oki Y; Murata Y; Kusumoto S; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Ohnishi T; Ohmori T
Anticancer Res; 2012 Dec; 32(12):5475-80. PubMed ID: 23225454
[TBL] [Abstract][Full Text] [Related]
18. Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
Wu Y; Lv C; Lin M; Hong Y; Du B; Yao N; Zhu Y; Ji X; Li J; Lai J
Front Immunol; 2023; 14():1297188. PubMed ID: 38022521
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.
Levy BP; Signorovitch JE; Yang H; Patterson-Lomba O; Xiang CQ; Parisi M
Curr Oncol; 2019 Jun; 26(3):e300-e308. PubMed ID: 31285672
[TBL] [Abstract][Full Text] [Related]
20. First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.
Chang Q; Zhang Y; Xu J; Zhong R; Qiang H; Zhang B; Han B; Qian J; Chu T
Thorac Cancer; 2019 May; 10(5):1043-1050. PubMed ID: 30900826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
